Treatment of chronic autoimmune urticaria with omalizumab

Slides:

Advertisements

Similar presentations

Control of immunopathology during chikungunya virus infection Caroline Petitdemange, PhD, Nadia Wauquier, PhD, Vincent Vieillard, PhD Journal of Allergy.

Advertisements

Trends in hospitalizations for anaphylaxis, angioedema, and urticaria in Australia, to Leanne M. Poulos, BMedSc (Hons), Anne-Marie.

D-dimer: A biomarker for antihistamine-resistant chronic urticaria

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Risk of an asthma exacerbation after bariatric surgery in adults

Pharmacologic rationale for treating allergic and nonallergic rhinitis

Clarification concerning amoxicillin skin testing

Fatty acids, inflammation, and asthma

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Increased IgE levels are linked to faster relapse in patients with omalizumab- discontinued chronic spontaneous urticaria Ragip Ertas, MD, Kemal Ozyurt,

Shyam Joshi, MD, David A. Khan, MD

Is 9 more than 2 also in allergic airway inflammation?

Desensitization to Chemotherapeutic Agents

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Fatty acids, inflammation, and asthma

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy Allen Kaplan, MD, Dennis Ledford,

Trends in hospitalizations for anaphylaxis, angioedema, and urticaria in Australia, to Leanne M. Poulos, BMedSc (Hons), Anne-Marie.

Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial Martin Metz, MD, Andrea Schütz, MD, Karsten Weller, MD, Marina.

Rising prevalence of asthma is sex-specific in a US farming population

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Test for Respiratory and Asthma Control in Kids (TRACK): A caregiver-completed questionnaire for preschool-aged children Kevin R. Murphy, MD, Robert.

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis George Philip, MD, Janet van Adelsberg, MD, Thomas Loeys, PhD, Nancy.

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria

Nonadherence to Asthma Treatment: Getting Unstuck

Peter M. Wolfgram, MD, David B. Allen, MD

Jewlya Lynn, PhD, Sophie Oppenheimer, MS, MPH, Lorena Zimmer, MA

Approaches to the diagnosis and management of patients with a history of nonsteroidal anti-inflammatory drug–related urticaria and angioedema Marek L.

Reply Journal of Allergy and Clinical Immunology

High eosinophil count: A potential biomarker for assessing successful omalizumab treatment effects William Busse, MD, Sheldon Spector, MD, Karin Rosén,

Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation Leif Bjermer, MD Journal of Allergy.

What are the best outcome measurements for atopic eczema

Cluster analysis and prediction of treatment outcomes for chronic rhinosinusitis Zachary M. Soler, MD, MSc, J. Madison Hyer, MS, Luke Rudmik, MD, MSc,

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Biosimilars and drug development in allergic and immunologic diseases

Reply Journal of Allergy and Clinical Immunology

Daphne Koinis-Mitchell, PhD, Timothy Craig, DO, Cynthia A

News Beyond Our Pages Journal of Allergy and Clinical Immunology

A cluster-randomized trial shows telephone peer coaching for parents reduces children's asthma morbidity Jane M. Garbutt, MB, ChB, Yan Yan, MD, PhD,

Sharon Seth, MD, David A. Khan, MD

What is an “eosinophilic phenotype” of asthma?

Medication use in children with asthma in Finland from 1995 to 2006

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Advances in the approach to the patient with food allergy

Geographic variability in childhood asthma prevalence in Chicago

High prevalence of severe asthma in a large random population study

A single intervention for cockroach control reduces cockroach exposure and asthma morbidity in children Felicia A. Rabito, PhD, MPH, John C. Carlson,

Syk expression and IgE-mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab Donald W. MacGlashan,

News Beyond Our Pages Journal of Allergy and Clinical Immunology

One step forward, 2 steps back: The enigma of preschool wheeze

Risk of oral food challenges

Benjamin Chaigne, MD, Hervé Watier, MD, PhD

Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency Marcel Levi, MD,

Pınar Uysal, MD, Esben Eller, MSc, PhD, Charlotte G

Measles and immunomodulation

Guus A. Westerhof, MD, Elise M. Vollema, MD, Els J

Partial improvement of solar urticaria after omalizumab

Macrolide antibiotics and asthma treatment

Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.

Asthma: The past, future, environment, and costs

Functional assessment of pathogenic IgG subclasses in chronic autoimmune urticaria Sridharan Soundararajan, PhD, Yoko Kikuchi, DVM, Kusumam Joseph, PhD,

Asthma Control Test: Reliability, validity, and responsiveness in patients not previously followed by asthma specialists Michael Schatz, MD, MS, Christine.

Environmental factors and eosinophilic esophagitis

Negative affect, medication adherence, and asthma control in children

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Clinical course and urinary eicosanoids in patients with aspirin-induced urticaria followed up for 4 years Malgorzata Setkowicz, MD, PhD, Lucyna Mastalerz,

Presentation transcript:

Treatment of chronic autoimmune urticaria with omalizumab Allen P. Kaplan, MD, Kusumam Joseph, PhD, Robert J. Maykut, MD, Gregory P. Geba, MD, MPH, Robert K. Zeldin, MD Journal of Allergy and Clinical Immunology Volume 122, Issue 3, Pages 569-573 (September 2008) DOI: 10.1016/j.jaci.2008.07.006 Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 UASs of 12 patients with chronic autoimmune urticaria treated with omalizumab for 16 weeks. A, Means and SDs of UASs of all 12 patients. Statistically significant decrements in symptom scores were observed at weeks 4, 8, 12, and 16. B, The response of 7 patients with complete resolution of symptoms. C, The response of 4 patients who had a partial improvement in symptoms. D, Single patient with no response. Journal of Allergy and Clinical Immunology 2008 122, 569-573DOI: (10.1016/j.jaci.2008.07.006) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 The use of hydroxyzine by 12 patients with chronic urticaria treated with omalizumab. Hydroxyzine was taken on an as-needed basis for a 20-week period by the study patients. A, Means and SDs of the use of hydroxyzine by all 12 patients. B, Patients with a marked response. C, Patients with partial response showing progressively less use of drug in most instances. D, The patient with no response. Journal of Allergy and Clinical Immunology 2008 122, 569-573DOI: (10.1016/j.jaci.2008.07.006) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Quality of life scores of patients with chronic urticaria treated with omalizumab for 16 weeks. Means and SDs of quality of life scores assessed at the time of each visit. Journal of Allergy and Clinical Immunology 2008 122, 569-573DOI: (10.1016/j.jaci.2008.07.006) Copyright © 2008 American Academy of Allergy, Asthma & Immunology Terms and Conditions